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Exponentially increased risk of infectious death in older renal seen at all ages of patients; however, it was noted that
transplant recipients. in older renal transplant patients, the relative benefit
Background. The benefit of renal transplantation for pa- appeared to be decreased when compared with youngertients with end-stage renal disease (ESRD) has been well doc-
patients. Other studies have confirmed the survival benefitumented. This benefit is seen throughout all age ranges of
of renal transplantation in the older ESRD patients [6, 7].patients. However, it has been documented that older renal
transplant recipients are at increased risk for death because of However, a recent multivariate analysis has indicated
infectious causes when compared with younger recipients. The that older renal transplant recipients were at a consider-
present study addresses whether this increased risk merely ably increased risk for death by infectious cause comparedparallels an age-related increase in infectious mortality or is
with younger patients [8]. This study did not look at wait-reflective of a particular vulnerability in older renal transplant
listed patients, and thus, the authors were unable to deter-recipients.
Methods. Patients wait-listed and transplanted between 1988 mine whether this was due to a normal age-related risk
and 1997 were analyzed utilizing the United States Renal Data or was exacerbated by the addition of immunosuppres-
System (USRDS) database. The primary study end point was
sion. In support of the concept that older renal transplantpatient death secondary to infection. Secondary end points
patients may be at increased risk of immunosuppression,included death secondary to cardiovascular cause and malig-
nancy. Cox-proportional hazard models were utilized with all a single center study noted an increase in serious infec-
pertinent variables. tions in older patients who received a more intensive
Results. Death related to infectious cause increased expo- immunosuppressive regimen as compared with older pa-
nentially in transplanted patients with increasing age (slope 5
tients who received a less intensive regimen [9].2.90.34x), while it increased linearly (slope 5 1.9x 1 8.6) with
The data mentioned previously in this article indicateincreasing age for those patients on the waiting list. Overall
mortality increases with age were equal between the wait-listed that older renal transplant recipients have an increased
and transplanted groups. risk of death secondary to infection as compared with
Conclusions. The overall survival benefit of transplantation younger renal transplant recipients. However, these pre-
is maintained in the older age groups. However, renal trans-
vious studies do not address whether this increase inplantation is associated with an increased risk for infectious
death by infection is merely reflective of an age-relateddeath beyond the expected age-related increased risk in patients
on the renal transplant waiting list. This may have an impact on trend in all patients with ESRD or a specific deleterious
future immunosuppressive regimens in this population. effect of post-transplant immunosuppression.
METHODSThe benefit of renal transplantation for patients with
end-stage renal disease (ESRD) has been well documented To compare the risk for infection-related mortality in
[1–4]. One recent study demonstrated a mortality benefit patients on the waiting list and after primary solitary renal
for patients receiving a renal transplant versus patients transplantation across age groups, we analyzed patients
who remained on the waiting list [5]. This benefit was registered as either transplanted or wait-listed in the U.S.
Renal Data System (USRDS) database between 1988 and
1997. The data for the analysis were provided by the
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U.S. Renal Transplant Scientific Registry and were sup-stage renal disease, chronic renal disease, kidney failure, immunosup-
pression. plemented with ESRD data from the USRDS. Patients
were followed from transplant date until death or theReceived for publication August 9, 2000
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Table 1. Demographic characteristics as compared with transplanted patients (R 2 5 0.99 and
0.95, respectively) was described by a linear relationship.Wait listed
Transplanted (never transplanted) In addition, the slope of the increase was almost identical
Age years 43.6612.7 48.3612.5 among the two study groups, 18.4 and 17.6 for wait-listed
Gender male/female 60%/40% 57.2%/42.8% and transplanted patients, respectively.
Race Caucasian/AA/other 70.7%/22.7%/6.5% 54.5%/37.1%/8.3%
Figure 2 displays the cross-sectional increase of theCause of ESRD
Glomerulonephritis 22.9% 18.7% risk for cardiovascular death by age group. As displayed
Hypertension 17.3% 22.7% in the figure, the best curve fit was obtained by a linear
Diabetes 26.4% 35.1%
equation (R 2 5 0.99 and 0.96 for wait-listed and trans-Polycystic 5.4% 2.3%
planted patients, respectively). The slope for transplantedAbbreviations are: AA, African American; ESRD, end-stage renal disease;
Polycystic; polycystic kidney disease. patients was almost half (6.1) as compared with the slope
for wait-listed patients (11.5).
Figure 3 shows that the best fit for the adjusted infec-
tious death rates by age group was exponential in the
follow-up. The primary study endpoint was patient death transplanted patients (R 2 5 0.99) as opposed to linear
secondary to infectious cause. Secondary study end- (R 2 5 0.96) in the wait-listed patients.
points were patient death, death secondary to cardiovas- Figure 4 displays the annual adjusted malignancy-
cular cause, and death secondary to malignancy. We used related mortality rates per 1000 patients by age group in
Cox proportional hazard models to estimate the impact wait-listed patients as compared with transplanted pa-
of age on the risk for patient death in patients on the tients. The best curve fit of the risk of death across age
waiting list as compared with transplanted patients. The groups for wait-listed patients as compared with trans-
Cox proportional hazard models were adjusted for age, planted patients (R 2 5 0.96 and 0.95, respectively) was
race, gender, and cause of ESRD. Age was used as a described by a linear relationship. In addition, the slope
categorized variable as follows: 18 to 29, 30 to 39, 40 to of the increase was higher for transplanted patients as
49, 50 to 59, 60 to 64, and more than 64 years. We opposed to wait-listed patients (1.5 vs. 1.1, respectively).
calculated annual adjusted mortality rates per 1000 pa-
tients by age group for patients on the transplant waiting
DISCUSSIONlist and transplanted patients. To get a cross-sectional
representation of the data, we plotted the adjusted mor- Our study demonstrates that the risk of dying of an
infectious cause is increased exponentially in older renaltality rates by age group as an X-Y scatter. We deter-
transplant recipients as compared with younger recipi-mined the best fitting curve of the resulting scatter for
ents. In contrast, in patients on the waiting list, the risktransplanted and wait-listed patients to obtain an esti-
of dying of an infection increases only linearly with ad-mate of the rate of increased mortality across age groups
vancing patient age. Thus, with age, the risk of dying ofvia the shape and slope of the best fitting curve. The
an infection increases in older transplant recipients to acurve fit was estimated by R 2. Multiple curve estimation
much greater degree than in patients on the waiting list.procedures (quadratic, cubic, exponential, power, in-
The most obvious reason for this would be an in-verse, s, log), were used to determine the best fit between
creased susceptibility to the immunosuppressive effectsage and adjusted mortality rates.
of antirejection medication. A large literature regardingA probability of type 1 error P 5 0.05 was considered
humans documents changes in immune function with ageto be the threshold of statistical significance. For multiple
and increased susceptibility to infections [10–19]. Thus, itcomparisons, the threshold of statistical significance was
seems plausible that immunosuppression, which is well-corrected by the Bonferroni adjustment. All statistical
tolerated in younger patients, may have more negativeanalyses were performed using SPSS software (version
effects in older patients. Our data indicate that the in-7.0 for Windows 95; SPSS, Inc., Chicago, IL, USA).
creased risk of dying of an infection in older renal trans-
plant patients is not only a function of the general trend
RESULTS toward more infectious vulnerability in older patients,
The demographic characteristics of the patients on but likely is also secondary to a specifically transplant-
the waiting list at time of wait listing and for and the related problem, that is, vulnerability of older patients
transplanted patients at the time of transplant are dis- to immunosuppression.
played in Table 1. Cardiovascular disease is the most frequent cause of
Figure 1 displays the annual adjusted mortality rates death in older patients. The fact that the overall mortality
per 1000 patients by age group in wait-listed patients as advantages of renal transplantation are maintained in
compared with transplanted patients. The best curve fit of older recipients makes it likely that the cardiovascular
benefit is also maintained. Our analysis supports thatthe risk of death across age groups for wait-listed patients
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Fig. 1. Mortality in wait-listed ( ) and trans-
plant patients (j). Annual adjusted death
rates are per 1000 patients.
Fig. 2. Mortality secondary to cardiovascular
disease in wait-listed ( ) and transplant pa-
tients (j). Annual adjusted death rates are
per 1000 patients.
Fig. 3. Mortality secondary to infectious dis-
ease in wait-listed ( ) and transplant patients
(j). Annual adjusted death rates are per 1000
patients.
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Fig. 4. Mortality secondary to malignancy in
wait-listed ( ) and transplant patients (j).
Annual adjusted death rates are per 1000 pa-
tients.
hypothesis. In addition, we found that the slope of the wait-listed patients) with age, and represents an increased
risk secondary to transplantation and more specificallyage-related mortality secondary to cardiovascular dis-
ease is almost twice as steep in patients on the waiting to poorer tolerance to immunosuppression.
On the other hand, the overall mortality benefit oflist compared with transplanted patients. This suggests
that with advancing age, patients have an increased bene- renal transplantation (including the immunosuppressive
medications used) versus wait list is maintained in olderfit in terms of cardiovascular mortality from transplanta-
tion. It is possible that this increasing benefit with age age groups. Both overall mortality and cardiovascular
mortality increase in both wait-listed and transplantedin part reflects a selection bias of patients who ultimately
receive a transplant as opposed to remaining on the patients with age, but the degree of increase (that is,
slope) is not greater in transplant patients.waiting list. However, it is doubtful that this would ex-
plain the full effect observed. Our study indicates that the benefits of renal transplan-
tation are maintained in older patients; however, theIt is intuitive that there is no advantage in transplanta-
poorer tolerance of these patients to infectious sequelaetion for malignancy-related mortality. In fact, our data
of immunosuppression deserves more focused attention.show a slight overall increase in malignancy-related death
rates in patients who underwent transplantation. The
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